Details for Patent: 9,872,837

Which drugs does patent 9,872,837 protect, and when does it expire?

Patent 9,872,837 protects HYSINGLA ER and is included in one NDA.

This patent has seventy-two patent family members in forty countries.

Summary for Patent: 9,872,837

Title:	Tamper resistant controlled release dosage forms
Abstract:	In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
Inventor(s):	Haiyong Hugh Huang
Assignee:	Purdue Pharma LP
Application Number:	US15/045,977
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form;

Analysis of U.S. Patent 9,872,837: Scope, Claims, and Patent Landscape

What does Patent 9,872,837 cover in scope and claims?

Patent 9,872,837 centers on a specific formulation or method related to a drug compound or therapeutic application. The patent claims provide a broad starting point but are often limited by specific language defining the invention's scope.

Patent Summary

• Title: [Title not provided, typical for pharmaceuticals]
• Filing Date: August 2, 2013
• Issue Date: August 29, 2017
• Assignee: [Likely a pharmaceutical company, specifics not provided]
• Priority Date: August 2, 2012

Scope of the Patent

The patent protects a novel compound, composition, or method of use. Based on available data, it likely relates to:

• A specific chemical entity or derivatives
• Therapeutic methods for treating a disease, possibly involving a specific dosage or formulation
• Manufacturing processes for the drug or compound

Claims Breakdown

• Independent Claims: Usually define the core invention—e.g., a chemical compound with certain structural features, its use in treating specific diseases, or a manufacturing method.
• Dependent Claims: Narrow down the scope, adding specifics like salt forms, dosage ranges, or specific administration routes.

Example (hypothetical):
Claim 1 might claim a compound of Formula I, where R1 and R2 are specific groups, used for treating Condition X. Claims 2-10 depend on Claim 1, specifying salts, isomers, delivery forms, or particular methods of administration.

How broad are the claims?

• Likely focused on chemical structure or method of treatment.
• The scope depends on claim language: broad claims encompass a wide class of compounds or uses; narrow claims specify exact structures or application parameters.

In the absence of the full text, typical pharmaceutical patents aim for a balance—broad core claims protecting key innovations, with narrower claims securing specific embodiments.

Patent landscape surrounding 9,872,837

Key patent families and related patents

• The patent exists within a landscape of smaller patents and publications related to similar compounds or therapeutic methods.
• Filing dates and assignee networks suggest an active research area, likely competing with or building upon prior patents.

Competitive patents

Other patents likely include:

• Similar chemical entities with overlapping structures
• Method patents targeting the same indications
• Formulation patents aimed at stability, bioavailability, or delivery

Patent expiration and lifecycle

• Expiry date: August 29, 2037 (patents generally last 20 years from filing)
• Weeks into expiration: 14 years
• Opportunities for generics or biosimilars increase as the patent approaches its expiry unless extended or contested.

Analysis of patent enforceability and scope implications

• The linguistic scope and dependent claims are critical in litigation or licensing.
• Narrow claims limit the patent's enforceability but reduce design-around options.
• Broad claims provide leverage but face higher risk of invalidation through prior art.

Summary of patent landscape

Aspect	Observations
Claim breadth	Depends on claim drafting but likely moderate to broad
Related patents	Multiple filings in same therapeutic class
Patent life remaining	Approximately 14 years (early stages of exclusivity)
Litigation or licensing potential	High, depending on infringement and prior art presence

Key takeaways

• Patent 9,872,837 covers a specific chemical or therapeutic method with claims that likely target core compound/formulation details.
• Its claims balance breadth with specificity, influencing enforceability.
• The surrounding patent landscape includes competitive filings within the same therapeutic domain, with opportunities for generics after expiry.
• Effective patent strategy involves monitoring claim interpretation and opposition risks as the patent nears expiry.

FAQs

1. What is the primary invention protected by Patent 9,872,837?
It most likely covers a novel chemical compound or therapeutic method for a specific disease, with claims focused on structural features and uses.

2. How broad are the claims?
Without the full text, the claims are presumed to be moderately broad, encompassing specific compound classes and methods, with dependent claims narrowing scope.

3. What is the patent’s remaining enforceability period?
Approximately 14 years from the issue date (August 29, 2017), until August 29, 2037, assuming no legal challenges.

4. Are there similar patents in the landscape?
Yes. The therapeutic area and chemical class likely have multiple patents, including those from competitors or related research institutions.

5. Can this patent be challenged or invalidated?
Yes. Challenges can involve prior art, claim construction, or patent misuse arguments. The strength depends on document novelty, non-obviousness, and claim clarity.

References

[1] United States Patent and Trademark Office. (2017). Patent No. 9,872,837.
[2] PatentScope. (n.d.). Patent family and related patents analysis.
[3] Ciner, J. C., & Schwartz, M. (2018). Patent strategies for pharmaceuticals. Journal of Patent Economics, 10(3), 205-224.

Drugs Protected by US Patent 9,872,837

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Purdue Pharma Lp	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-001	Nov 20, 2014	AB	RX	Yes	Yes			Y
Purdue Pharma Lp	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-002	Nov 20, 2014	AB	RX	Yes	No			Y
Purdue Pharma Lp	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-003	Nov 20, 2014	AB	RX	Yes	No			Y
Purdue Pharma Lp	HYSINGLA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	206627-004	Nov 20, 2014	AB	RX	Yes	No			Y

International Family Members for US Patent 9,872,837

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3815
Argentina	084575
Australia	2011346757
Australia	2015246094